Xeris Biopharma Holdings, Inc. (0A8E.L)

USD 3.29

(-4.76%)

Revenue Summary of Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc.'s latest annual revenue in 2024 was 163.91 Million USD , up 48.68% from previous year.
Xeris Biopharma Holdings, Inc.'s latest quarterly revenue in 2024 FY was 163.91 Million USD , up 48.68% from previous quarter.
Xeris Biopharma Holdings, Inc. reported a annual revenue of 110.24 Million USD in annual revenue 2023, down 0.0% from previous year.
Xeris Biopharma Holdings, Inc. reported a annual revenue of 110.24 Million USD in annual revenue 2022, up 122.32% from previous year.
Xeris Biopharma Holdings, Inc. reported a quarterly revenue of 163.91 Million USD for 2024 FY, up 48.68% from previous quarter.
Xeris Biopharma Holdings, Inc. reported a quarterly revenue of 40.63 Million USD for 2024 Q3, down -8.45% from previous quarter.

Annual Revenue Chart of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Historical Annual Revenue of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Year	Revenue	Revenue Growth
2024	163.91 Million USD	48.68%
2023	110.24 Million USD	0.0%
2022	110.24 Million USD	122.32%
2021	49.59 Million USD	146.04%
2020	20.15 Million USD	717.65%
2019	2.46 Million USD	58.42%
2018	1.55 Million USD	44.74%
2017	1.07 Million USD	0.0%

Year	Revenue	Revenue Growth
2024 Q1	48.32 Million USD	27.13%
2024 FY	163.91 Million USD	48.68%
2024 Q3	40.63 Million USD	-8.45%
2024 Q4	48.06 Million USD	18.28%
2024 Q2	44.39 Million USD	-8.13%
2023 FY	110.24 Million USD	0.0%
2023 Q4	38 Million USD	14.5%
2023 Q3	33.19 Million USD	-12.66%
2023 Q2	38 Million USD	27.87%
2023 Q1	29.72 Million USD	17.46%
2022 Q2	21.42 Million USD	94.19%
2022 Q1	11.03 Million USD	23.91%
2022 FY	110.24 Million USD	122.32%
2022 Q4	25.3 Million USD	14.65%
2022 Q3	22.07 Million USD	3.01%
2021 Q3	8.05 Million USD	13.57%
2021 Q2	7.08 Million USD	-24.97%
2021 FY	49.59 Million USD	146.04%
2021 Q1	9.44 Million USD	366.11%
2021 Q4	8.9 Million USD	10.62%
2020 FY	20.15 Million USD	717.65%
2020 Q1	323 Thousand USD	0.94%
2020 Q4	2.02 Million USD	13.37%
2020 Q3	1.78 Million USD	-4.08%
2020 Q2	1.86 Million USD	477.09%
2019 Q2	801 Thousand USD	37.63%
2019 Q4	320 Thousand USD	29.03%
2019 FY	2.46 Million USD	58.42%
2019 Q1	582 Thousand USD	-28.94%
2019 Q3	248 Thousand USD	-69.04%
2018 Q2	467 Thousand USD	174.71%
2018 FY	1.55 Million USD	44.74%
2018 Q4	819 Thousand USD	211.41%
2018 Q3	263 Thousand USD	-43.68%
2018 Q1	170 Thousand USD	-69.91%
2017 Q3	354 Thousand USD	0.0%
2017 Q4	565 Thousand USD	59.6%
2017 FY	1.07 Million USD	0.0%

Peer Revenue Comparison of Xeris Biopharma Holdings, Inc.

Name	Revenue	Revenue Difference
Arrowhead Pharmaceuticals, Inc.	240.73 Million USD	31.911%
Codexis, Inc.	70.14 Million USD	-133.685%
Viridian Therapeutics, Inc.	314 Thousand USD	-52101.911%
Organovo Holdings, Inc.	109 Thousand USD	-150279.817%